SNDX-5613 (Synonyms: SNDX-5613) |
| Catalog No.GC39508 |
SNDX-5613 es un inhibidor de Menin-MLL potente y especÍfico con una Ki de uniÓn de 0,149 nM y una IC50 basada en células de 10-20 nM. SNDX-5613 se puede utilizar para la investigaciÓn de leucemias agudas con reordenamiento de MLL (MLL-r), incluida la leucemia linfoblÁstica aguda (LLA) y la leucemia mieloide aguda (LMA).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2169919-21-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SNDX-5613 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].
[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *